CCL5 and pancreatic neoplasm: In our study, higher baseline CCL5 levels were observed in CR/PR/SD (33.1 ng/ml) compared to PD (23.2 ng/ml), suggesting that plasmatic CCL5 may be a predictive biomarker for VT1021 in patients with GBM and pancreatic cancer (Table 5).